LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY
Xavier Thomas(Hôpital Lyon Sud), Gilles Salles(Memorial Sloan Kettering Cancer Center), Marie Balsat(Hôpital Claude Huriez), Mohamed Elhamri(Hôpital Edouard Herriot), Sandrine Loron(Hôpital de la Croix-Rousse), Marica Laurino(Hospices Civils de Lyon), Fiorenza Barraco(Hôpital Lyon Sud), Marie‐Virginie Larcher, Alexandre Deloire(Lyon 1 Université), Gaëlle Fossard(Hospices Civils de Lyon), Myriam Renault(Hospices Civils de Lyon), Eric Wattel(Université Claude Bernard Lyon 1), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Maël Heiblig(Université Claude Bernard Lyon 1)
Cited by 5
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
|Blood|1994|581
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431